Kezar Life Sciences, Inc. (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Company from $11.00 to $9.00. They now have an "equal weight" rating on the stock.
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $11.00. They now have an "equal weight" rating on the stock.
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "market perform" rating re-affirmed by analysts at William Blair.
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]